Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
Viatris reported positive top-line Phase 3 results for VR-205 in Japanese adults with primary IgAN, showing a 33.75% reduction in urine protein-to-creatinine ratio at nine months. The drug met all key secondary endpoints, including significant eGFR improvement, and was well tolerated with a safety profile consistent with global studies. The company targets submission of a New Drug Application in Japan by the end of 2026 for this asset, already marketed as Tarpeyo in the U.S.
Key figures
- Drug Name
- VR-205 (targeted-release budesonide formulation)
- Phase Of Trial
- Phase 3
- Dosage
- 16 mg
- P value
- < 0.001
- Upcr reduction
- 33.75 percent
- Participant count
- 39
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.